Recent developments in the prevention and treatment of Epstein–Barr virus-associated lymphoproliferative diseases

Author： Meerbach Astrid   Gruhn Bernd   Wutzler Peter  

Publisher： Informa Healthcare

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.14, Iss.4, 2004-04, pp. : 527-547

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Ciclosporin: Epstein-Barr virus-associated lymphoproliferative disorder: case report

By  

Reactions Weekly, Vol. 1, Iss. 1047, 2005-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Cyclophosphamide/everolimus/fludarabine: Fatal Epstein-Barr virus-associated lymphoproliferative disorder in an elderly patient: case report

By  

Reactions Weekly, Vol. 1, Iss. 1174, 2007-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

Immunosuppressants: Haemophagocytic lymphohistiocytosis triggered by Epstein-Barr virus-associated post-transplant lymphoproliferative disorder: case report

By  

Reactions Weekly, Vol. 1, Iss. 1424, 2012-01 ,pp. : 31-32

Adis International

Access to resources Recommend Favorite

Antithymocyte globulin/ciclosporin: Epstein-Barr virus-associated lymphoproliferative disorder in an elderly patient: case report

By  

Reactions Weekly, Vol. 1, Iss. 1400, 2012-01 ,pp. : 9-10

Adis International

Access to resources Recommend Favorite

Infliximab: Epstein-Barr virus associated lymphoproliferative disorder: case report

By  

Reactions Weekly, Vol. 1, Iss. 1283, 2010-01 ,pp. : 53-54

Adis International

Access to resources Recommend Favorite